XML 44 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings (Loss) per Share
12 Months Ended
Dec. 31, 2022
Earnings (Loss) per Share
NOTE 18—Earnings (loss) per share:
The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2022, 2021 and 2020 are as follows:
 
 
  
Year ended December, 31
 
 
  
    2022  
 
  
    2021  
 
  
    2020  
 
 
  
(U.S. $ in millions, except share data)
 
Net income (loss) used for the computation of basic and diluted earnings (loss) per share
     (2,353 )    $ 417      $ (3,990
    
 
 
    
 
 
    
 
 
 
Weighted average number of shares used in the computation of basic earnings (loss) per share
     1,110        1,102        1,095  
    
 
 
    
 
 
    
 
 
 
Weighted average number of shares used in the computation of diluted earnings (loss) per share
     1,110        1,107        1,095  
    
 
 
    
 
 
    
 
 
 
Basic earnings (loss) per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested RSUs and PSUs during the period), net of treasury shares.
In computing diluted loss per share for the year ended December 31, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and
non-vested
RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.
In computing diluted earnings per share for the year ended December 31, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and
non-vested
RSUs and PSUs granted under employee stock compensation plans, amounting to 5 million weighted average shares, using the treasury stock method. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.
In computing diluted loss per share for the year ended December 31, 2020, no account was taken of the potential dilution that could occur upon the exercise of options and
non-vested
RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.
Basic and diluted loss per share was $2.12 for the year ended December 31, 2022, compared to basic and diluted earnings per share of $0.38 for the year ended December 31, 2021 and basic and dilute
d
loss per share of $3.64 for the year ended December 31, 20
20
, respectively.